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ABSTRACT
Background: Literature review suggests that adherence to immunosuppressive drugs may be lower in 
recipients of living than of deceased donor kidney grafts, possibly because of profile differences.
Objective: To compare the level of immunosuppressive adherence levels between patients with deceased 
and living (-related; -unrelated) donor grafts in Switzerland.
Methods: Using data from two similar cross-sectional studies at two transplant centers in Switzerland, 
the level of adherence between the two groups was compared. Medication adherence was assessed by 
self-report or electronic monitoring. Possible explanatory factors included age, beliefs regarding immu-nosuppressive drugs, depressive symptomatology, pre-emptive transplantation, and the number of trans-
plants received, were also considered. Data were analyzed using logistic regression analysis. 
Results: Unadjusted non-adherence odds were 2 to 3 times higher in living-related than deceased do-
nor transplantation (ORs: 2.09-3.05; p<0.05). Adjustment for confounders showed that these differences were associated most with the younger age of living-related subjects and the belief that immunosuppres-
sive drugs are less important for living-related donations. 
Conclusion: There is a lower immunosuppressive adherence in recipients of living-related donor kidneys, 
possibly owing to differences in patient profile (ie, health beliefs regarding their immunosuppressive 
needs), knowledge of which may enhance adherence if addressed.
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INTRODUCTION
Transplantation is a cost-effective treat-ment for patients with end-stage renal disease [1, 2], providing them with 
improved quality of life and good long-term 
survival prospects. Survival rates are especial-
ly favorable for those who receive kidneys from 
living donors [3, 4], even under conditions of 
suboptimal tissue matching [5, 6], and where 
levels of non-adherence to immunosuppres-
sive medication are comparatively high [7-11]. 
Higher non-adherence levels observed in re-
cipients of living donor grafts have previously 
been attributed to a sense of relative invul-
nerability resulting from recipients’ younger 
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age and to the possibility that those receiving 
grafts from relatives believe that their higher 
histocompatibility protects them adequately 
against rejection [9]. Also, a strong sense of 
obligation towards the donor overburdening 
these patients [12], or limited experience with 
self-management of chronic illness (eg, less ex-
perience with dialysis), implying fewer accu-
mulated skills necessary to master a chronic 
condition such as living with a transplant [10, 
13], are suggested as explanations for this 
group’s higher non-adherence levels. Because 
of the shortage of empirical data regarding the 
existence and/or extent of the supposed non-
adherence differences, the primary objective of 
this study was to examine whether adherence 
differences could be detected between recipi-
ents of different types of kidney grafts. Should 
such differences be confirmed, our second goal 
was to examine a selection of variables acting 
as possible confounders. 
MATERIALS AND METHODS
Two cross-sectional adherence studies in kid-
ney transplant recipients were performed at 
the transplant centers of Zürich and Basel 
(Switzerland), approved by the responsible 
ethical committees (Ethikkommission Zürich 
07/12.9.207; Ethikkommssion beider Basel 
55/00; Überregionale Ethikkommision für 
klinische Forschung PV124/00-SNF). The 
studies differed from each other in their mea-
surement of the number of variables reflect-
ing possible reasons for adherence differences, 
but were similar in their measurement of the 
key variables, ie, adherence and graft type, the 
latter of which added to the literature in that, 
alongside deceased donation, it subdivided the 
living donation group into “living-related” 
and “living-unrelated.”
The Zürich study
Design, Sample and Setting
The first source of data was a study conducted 
at the nephrology outpatient clinic at Uni-
versity Hospital Zürich [14], which is a site 
of about 85 renal transplants per year [15]. 
Patients were recruited consecutively during 
their follow-up visits. To qualify for inclusion, 
they had to be adult kidney transplant recipi-
ents one to five years after their first trans-
plant, managing their medication indepen-
dently, and able to write in German. Patients 
who lacked mental acuity were excluded. 
Procedure
Clinical variables were retrieved from partici-
pants’ medical files, including graft donor type 
(deceased, living-related, living-unrelated) 
and pre-emptive transplantation status (yes/
no). Demographic and adherence data were 
assessed by interview. The item “how often 
have you not taken immunosuppressive medi-
cation in the past four weeks?” was selected 
as a measure of “taking adherence” from the 
4-item Basel Assessment of Adherence Scale 
for Immunosuppressives (BAAS-IS) [16, 17]. 
The Basel study 
Design, Sample and Setting
The second source of data was a study con-
ducted at the nephrology outpatient clinic of 
the University Hospital Basel [10], a similar-
ly sized center conducting approximately 70 
transplants annually [15]. The study’s conve-
nience sample consisted of adult patients who 
were German or French speaking, literate, at 
least one year post-renal transplant, indepen-
dently managing their immunosuppressive 
regimens, able to respond adequately to the 
researchers’ questions, and/or able to fill out 
the questionnaires.
Procedure
Patients were recruited during their annual 
check-up visits to the hospital, when demo-
graphic and adherence data were collected. 
Clinical variables retrieved from the patients’ 
medical files included graft donor type (de-
ceased, living-related and living-unrelated), 
pre-emptive transplantation status (yes/no), 
number of HLA-mismatches, and number of 
transplants received. Depressive symptomatol-
ogy was measured using the 21-item, 4-point 
Beck Depression Inventory [18, 19]. Patient 
beliefs with regard to immunosuppressive 
medications were also measured via a single-
item measuring the respondent’s belief that an 
individual who receives a living donor kidney 
does not need as much immunosuppressive 
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medication as a person who receives a kidney 
from a deceased donor. This was assessed on 
a 5-point Likert scale ranging from complete 
disagreement (‘1’) to complete agreement (‘5’). 
Non-adherence was assessed identically to the 
Zürich study [20].
A subsample of patients agreed to elec-
tronic adherence monitoring by means of a 
MEMS®-V TrackCap system (Aardex, Ltd.) 
[21]. The MEMS® uses a medication bottle 
fitted with a cap containing a chip registering 
the time and date of every opening. For this 
analysis, taking adherence was defined as the 
ratio of registered openings to the number of 
prescribed doses [22]. For analytical reasons, 
the resulting data were transformed into three 
ordinal categories analogous to those used for 
self-reported non-adherence. 
Data analysis 
The two studies were analyzed separately. 
Data were not pooled to allow separate cor-
roboration of our main hypothesis in the two 
different settings. Moreover, the Zürich study 
did not have the extended set of confound-
ing factors. Variables were described using 
percentages, means and standard deviations. 
Simple comparisons of demographic and clini-
cal variables between graft types were per-
formed using χ2 and Mann-Whitney U tests. 
Testing for differences in adherence levels be-
tween graft types was done by ordinal logistic 
regression analysis [23], which calculated the 
Table 1: Demographic and clinical characteristics of the sample. Numbers are frequency (%) or mean±SD.
Variable Zürich study  (n=114) Basel study  (n=348)
Male gender 74 (64%) 207 (58%)
Not living alone 15 (13%) 83 (23%)
Higher education 24 (21%) 99 (27%)
Swiss nationality 87 (76%) 291 (81%)
Graft type
Deceased 56 (49%) 210 (59%)
Living-related 28 (25%) 102 (29%)
Living-unrelated 30 (26%) 43 (12%)
Immunosuppressive (cyclosporine) 47 (41%) 228 (64%)
Drugs
Tacrolimus 55 (48%) 64 (18%)
Sirolimus 11 (9%) 25 (7%)
Azathioprine 13 (11%) 115 (32%)
Corticosteroids 40 (35%) 93 (26%)
Mycophenolate Mofetil 100 (87%) 170 (47%)
Mean±SD age 53.6±119 52.9±13.5
Self-reported adherence
Adherent 96 (84.2%) 308 (88.3%)
Non-adherent once a month 11 (9.7%) 28 (8.0%)
Non-adherent ≥every 2 weeks 7 (6.1%) 13 (3.7%)
Mean±SD taking adherence (EM*) — 97.3±8.9
*EM: Electronic monitoring
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probability that each patient was adherent. Sec-
ondary hypotheses were tested by adding the 
confounding variables of age, the belief that an 
individual who receives a living donor kidney 
does not need as much immunosuppressive 
medication as a person who receives one from 
a deceased donor, depressive symptomatology, 
number of pre-emptive transplantations, and 
number of transplants to the model. Analyses 
were performed using SAS version 9.1.3 (SAS 
Institute, NC, Cary).
RESULTS 
Sample characteristics 
Sample characteristics are outlined in Table 1. 
The Zürich study included 114 kidney trans-
plant patients (74% of them eligible). The Ba-
sel study included 348 patients (86% of them 
eligible), of whom 248 had been assessed using 
electronic monitoring (60% of them eligible). 
In the Zürich study, half (51%) of the patients 
had received kidneys from living donors. In 
the Basel study, this figure was slightly lower 
(41%). Living-related and -unrelated grafts 
were represented equally in the Zürich study, 
whereas living-related donation was more 
prevalent in the Basel study (70% of living 
donations). In both studies, the mean age was 
53 years; few were young adults (only three in 
each study were between 18 and 25 years).
Table 2 shows that graft types did not differ 
with respect to the number of transplants or 
the levels of depressive symptoms. However, 
living-related transplant patients were young-
er, had a higher proportion of pre-emptive 
Table 2: Distribution of confounding factors 
Variable Graft type
Zürich study* 
(n=114)
p value
Basel study*
(n=348)
p value
Age (mean±SD)
Deceased 56.4±10.6
<0.001
56.7±13.6
<0.001Living-related 45.8±14.4 44.8±11.0
Living-unrelated 55.4±8.0 54.3±9.5
Pre-emptive transplantation† 
(frequency, %)
Deceased 2 (8%)
<0.001
3 (8%)
<0.001Living-related 13 (50%) 21 (54%)
Living-unrelated 11 (42%) 15 (39%)
Health belief “with a 
living donor kidney, fewer 
immunosuppressives are 
needed as with a deceased 
donor kidney” (mean±SD)
Deceased — 2.13±1.19
<0.001 
Living-related — 2.72±1.44
Living-unrelated — 1.93±1.27
Number of transplants 
(mean±SD)‡
Deceased — 1.15±0.41
0.79 Living-related — 1.16±0.46
Living-unrelated — 1.09±0.29
Number of mismatches 
(mean±SD)
Deceased — 4.75±1.30
<0.001Living-related — 2.96±1.91
Living-unrelated — 5.05±0.84
Depressive symptomatology 
(mean±SD)
Deceased — 0.36±0.32
0.35 Living-related — 0.36±0.33
Living-unrelated — 0.29±0.26
*χ² and Mann-Whitney U tests
†Recipients of transplants from a deceased donor who did not receive dialysis prior to transplantation were coded as pre-emptive 
‡Graft type of last transplantation reported
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transplantations, showed fewer mismatches 
and had a stronger belief that an individual 
who receives a living donor kidney requires 
less immunosuppressive medication than one 
who receives a deceased-donor graft. 
Differences in non-adherence among 
graft type groups
In both studies living-unrelated graft recipi-
ents had adherence levels similar to those of 
deceased-donor recipients (Table 3). Similarly, 
self-reported non-adherence was significant-
ly higher in recipients of living-related than 
in deceased grafts in both the Zürich study 
(OR=3.14; 95% CI: 1.01–9.82) and the Ba-
sel study (OR=2.09; 95% CI: 1.04–4.17). The 
same was true for electronically measured 
non-adherence (OR=2.12; 95% CI: 1.13–3.98). 
The extent to which confounding factors ex-
plain these latter adherence differences can 
be inferred by comparing the unadjusted ORs 
of Table 3 with their adjusted counterparts in 
Table 4. Controlling for the confounders low-
ered estimated self-reported non-adherence 
differences between living-related and de-
ceased transplantation from unadjusted sig-
nificant ORs between 2 and 3, to adjusted in-
significant values of 1.08 in the Zürich study 
(95% CI: 0.25–4.60; p=0.92), 1.26 for the Basel 
study self-report (95% CI: 0.48–3.29; p=0.63), 
and 1.98 for the Basel study electronic moni-
toring (95% CI: 0.92–4.26; p=0.08). 
A single confounder’s contribution to explain-
ing adherence differences between deceased 
and living-related transplants was inferred by 
omitting one explanatory variable at a time 
from the model (Table 5), revealing that es-
timated ORs were affected most by omitting 
age and the belief that an individual who re-
ceives a living donor kidney needs less immu-
nosuppressive medication than the recipient 
of a deceased-donor graft. The effect of pre-
emptive transplantation on the ORs differed 
between the studies.
DISCUSSION 
Our analysis confirmed the observation that 
adherence differences exist between recipients 
of different types of kidney graft, however, in-
dicated living-related transplantations as the 
factor responsible for the lower adherence in 
the larger living donor transplantation group. 
The living-unrelated recipients showed adher-
ence levels similar to those of deceased donor 
transplant recipients, which suggests that re-
latedness is at the core of the observed adher-
ence differences, rather than the fact that the 
donor is alive and known to the recipient, as is 
true in most cases. This in turn agrees with 
our second analytic finding, ie, that the belief 
that an individual who receives a living-donor 
kidney needs less immunosuppressive medica-
Medication adherence in kidney transplantation
Table 3: Unadjusted logistic regression model
Variable Graft type OR (95% CI) R²
Zürich study (SR*) Deceased vs living-related 3.14 (1.01–9.82)
6.5%Deceased vs living-unrelated 0.80 (0.19–3.34)
Unrelated vs related 3.93 (0.92–16.7)
Basel study (EM†) Deceased vs living-related 2.12 (1.13–3.98)
3.0%Deceased vs living-unrelated 1.39 (0.57–3.39)
Unrelated vs related 1.53 (0.60–3.93)
Basel study (SR) Deceased vs living-related 2.09 (1.04–4.17)
2.2%Deceased vs living-unrelated 1.02 (0.33–3.16)
Unrelated vs related 2.05 (0.65–6.46)
*SR: Self-reported; †EM: Electronic monitoring
The coefficient of determination (R²) was calculated by the method presented by Nagelkerke, et al. 
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tion than a deceased-donor kidney recipient 
contributed more than any other variable to 
the adherence difference. A sense of immu-
nity to rejection in this group may indeed 
be a major factor promoting non-adherence 
[9]. While the explanatory power of the be-
lief was considerable in the self-report model, 
its association with adherence was lower with 
electronic monitoring, possibly because indi-
viduals acknowledging non-adherent behavior 
may be more willing to admit beliefs oppos-
ing the health care provider’s. Age was also 
found to be an independent explanatory factor 
[9]. The effect of age, however, may have been 
underestimated in this analysis, as the clinical 
prototype of related donation—a young adult 
receiving a kidney from a parent, was uncom-
mon in our sample.
K. Denhaerynck, G. Schmid-Mohler, et al
Table 4: Adjusted logistic regression model
Analysis Variable OR (95% CI) R²
Zürich study (SR*)
Graft type
Deceased vs living-related† 1.08 (0.25–4.60)
15.3%Deceased vs living-unrelated 0.48 (0.09–2.44)
Unrelated vs related 2.24 (0.47–10.7)
Controlled for
Age 1.06 (1.01–1.11)
Pre-emptive transplantation 0.30 (0.08–1.13)
Basel study (EM‡)
Graft type
Deceased vs living-related† 1.98 (0.92–4.26)
9.6%Deceased vs living-unrelated 1.76 (0.65–4.77)
Unrelated vs related 1.12 (0.38–3.28)
Controlled for
Age 1.02 (1.00–1.05)
Health belief 0.85 (0.67–1.06)
Number of mismatches§ 0.92 (0.75–1.14)
Pre-emptive transplantation 1.29 (0.44–3.74)
Number of transplantations 0.57 (0.32–1.04)
Depressive symptoms 0.53 (0.22–1.21)
Basel study (SR)
Graft type
Deceased vs living-related† 1.26 (0.48–3.29)
8.1%Deceased vs living-unrelated 1.06 (0.31–3.65)
Unrelated vs related 1.18 (0.32–4.43)
Controlled for…
Age 1.02 (0.99–1.05)
Health belief 0.71 (0.55–0.92)
Number of mismatches 1.04 (0.83–1.29)
Pre-emptive transplantation 0.80 (0.28–2.31)
Number of transplantations 1.00 (0.41–2.43)
Depressive symptoms 1.28 (0.38–4.26)
*SR: Self-reported
†Estimate to be compared with in Table 5
‡EM: Electronic monitoring
§Matching was added as a variable to be able to estimate the effect of the belief in the need for less immunosuppressives regardless of the 
actual histocompatibility
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Pre-emptive transplantation
The seemingly large effect of pre-emptive 
transplantation on adherence differences ob-
served in the Zürich is thus very likely a sta-
tistical deviation invoked by the small sample 
size of dialysisless transplantations in the 
deceased donor reference category (ie, n=2). 
Further evidence that pre-emptive transplan-
tation does not contribute to post-transplanta-
tion adherence levels arises from the fact that 
living-unrelated transplant recipients (where 
pre-emptive transplantation is also common 
practice) show adherence levels similar to 
those of deceased donor transplants. 
A limitation of the study is that we did not 
have access to variables characterizing the re-
lationship between living-(un)related donors 
and recipients, such as the perceived closeness 
or quality of the donor-recipient relationship. 
The emotional bond of the donor-recipient 
pair may be an important extra-confounding 
factor to be investigated.
In conclusion, our analysis supported the hy-
pothesis of lower adherence to immunosup-
pressive medication in living-related kidney 
transplants, an association we found to be a 
proxy of underlying risk factors, which the 
modifiable risk factor “patients beliefs” (rath-
er than experience with chronic illness) is an 
example of. The finding may help identifying 
patients at risk for rejection, which is report-
edly more frequent and severe in this patient 
population [24], and to which non-adherent 
behavior has been shown to contribute.
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Table 5: Contribution of single variables to the logistic regression model. This Table provides an estimation 
of the relative contribution of explanatory variables to explaining adherence differences between deceased vs 
living-related graft recipients. The odds ratio represents the contrast between deceased vs living-related graft 
recipients in the absence of the respective variable, which can be compared to Table 4.
Variable omitted from the 
regression model
Parameters for contrasting deceased vs 
living-related graft recipients
Adjusted OR (95% CI)
R²
Zürich study (SR*)
Age 2.11 (0.57–7.84) 8.7%
Pre-emptive transplantation 2.01 (0.57–6.97) 11.5%
Basel study (EM†)
Age 2.38 (1.14–5.00) 8.1%
Health belief 2.02 (0.94–4.31) 8.2%
Number of mismatches 1.70 (0.83–3.45) 9.3%
Pre-emptive transplantation 1.91 (0.90–4.05) 9.6%
Number of transplantations 1.91 (0.88–4.12) 7.9%
Depressive symptoms 1.94 (0.91–4.14) 7.6%
Basel study (SR)
Age 1.65 (0.67–4.02) 6.9%
Health belief 1.53 (0.60–3.90) 4.7%
Number of mismatches 1.34 (0.56–3.21) 8.0%
Pre-emptive transplantation 1.35 (0.53–3.39) 8.1%
Number of transplantations 1.26 (0.48–3.28) 8.1%
Depressive symptoms 1.25 (0.48–3.25) 8.0%
*SR: Self-reported
†EM: Electronic monitoring
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